$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
What is the difference between Acotiamide and Mosapride
2026-02-01 22:25:32
Check Details
Latest news on Vebreltinib drug donation policy
2026-02-01 22:25:32
Check Details
How effective is the treatment with Delamanid/Delba? clinical effect
2026-02-01 22:25:32
Check Details
How to deal with the emergence of resistance to Deflazacort
2026-02-01 22:25:32
Check Details
What are the main differences between Guanfacine and Clonidine?
2026-02-01 22:25:32
Check Details
Where to buy Acotiamide
2026-02-01 22:25:32
Check Details
What are the indications for Vebreltinib?
2026-02-01 22:25:32
Check Details
Why China doesn’t ban Delamanid use
2026-02-01 22:25:32
Check Details
Where can Deflazacort be purchased?
2026-02-01 22:25:32
Check Details
Is Guanfacine easily available in pharmacies?
2026-02-01 22:25:32
Check Details
What is the dosage of Acotiamide?
2026-02-01 22:25:32
Check Details
What are the medical insurance reimbursement conditions for Vebreltinib?
2026-02-01 22:25:32
Check Details
1
2
...
2008
2009
2010
2011
2012
2013
2014
...
10226
10227
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Sabril (Vigabatrin) Explained: Indications, Vision Loss Risk & Key Warnings
2
FDA Approves Tauklarify for Tau PET Imaging in Alzheimer's Disease Assessment
3
First CELMoD Drug Zenbexus Wins FDA Accelerated Approval for Multiple Myeloma
4
Elamipretide Side Effects and Medication Safety Guide: Injection Site Reactions and Storage Essentials
5
Dutasteride Soft Capsules: Comprehensive Side Effect Profile and Management Strategies
6
Oral Semaglutide Tablets: A Complete Guide to the GLP-1 Receptor Agonist for Type 2 Diabetes and Cardiovascular Protection
7
Sotorasib (Lumakras): A Comprehensive Guide to the First KRAS G12C-Targeted Inhibitor
8
Comprehensive Interpretation of Osimertinib: Efficacy, Side Effects and Medication Standards
9
Sotorasib: Can the First KRAS G12C-Targeted Therapy Cure Cancer?
10
Trametinib (Mekinist): Refrigerated Storage, Fasting Administration, and BRAF Mutation Indications Explained
11
Asciminib (SCEMBLIX): STAMP Inhibitor Dosing Guide and Nomenclature Clarification for CML
12
Belzutifan (Welireg): HIF-2α Inhibitor for VHL-Associated Tumors and Renal Cell Carcinoma — Dosing Phases, Survival Data, and Efficacy Insights